e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
H. Wilkens, U. Mack, K. Rentz, B. Weingard, G. W. Sybrecht (Homburg, Germany)
Source:
Annual Congress 2005 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Thematic Poster Session
Number:
3620
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Wilkens, U. Mack, K. Rentz, B. Weingard, G. W. Sybrecht (Homburg, Germany). Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis. Eur Respir J 2005; 26: Suppl. 49, 3620
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Related content which might interest you:
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir Mon 2012; 57: 148-160
Year: 2012
Treatment of pulmonary hypertension
Source: Virtual Congress 2020 – Treatment in pulmonary hypertension
Year: 2020
Pulmonary hypertension in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Source: Eur Respir J 2007; 30: 715-721
Year: 2007
Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension
Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017
Year: 2018
Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
Source: Eur Respir J 2015; 46: 1370-1377
Year: 2015
When is pulmonary hypertension not pulmonary hypertension?
Source: Eur Respir J 2001; 18: Suppl. 33, 522s
Year: 2001
Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
Sarcoidosis-associated pulmonary hypertension
Source: Eur Respir Monogr 2022; 96: 234-255
Year: 2022
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept